TrialJAMA dermatology2020

Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.

Andrew Blauvelt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.